Dianthus Therapeutics, Inc. /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dianthus Therapeutics, Inc. /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $6.24M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.83M | Mar 11, 2025 |
| FY2019 | Dec 31, 2019 | $0 | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | $0 | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | $0 | Mar 3, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 3, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Mar 3, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Mar 3, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $6.24M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.83M | Mar 11, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($162.34M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($84.97M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($43.56M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($28.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($71.14M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($74.94M) | Mar 8, 2022 |
| FY2019 | Dec 31, 2019 | ($23.24M) | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | ($20.99M) | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | ($17.71M) | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | ($14.83M) | Mar 3, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($177.93M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($101.86M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($48.17M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($29.71M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($74.69M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($78.70M) | Mar 8, 2022 |
| FY2019 | Dec 31, 2019 | ($24.64M) | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | ($22.64M) | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | ($19.34M) | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | ($16.35M) | Mar 3, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.64M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $83.11M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $32.84M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $29.38M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $46.77M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $50.62M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $59.21M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $41.34M | Mar 3, 2020 |
| FY2019 | Dec 31, 2017 | $27.90M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $5.78M | Mar 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($129.06M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($78.18M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($36.86M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($29.07M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($59.53M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($64.02M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($57.10M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($41.89M) | Mar 3, 2020 |
| FY2019 | Dec 31, 2017 | ($22.26M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($6.53M) | Mar 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $314.0K | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $400.0K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $3.06M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $7.67M | Mar 3, 2020 |
| FY2019 | Dec 31, 2017 | $2.20M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $139.0K | Mar 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $530.92M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $374.01M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $179.41M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $83.11M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $189.93M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $161.62M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $161.51M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $157.31M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $54.46M | Mar 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.52M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $21.53M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $10.54M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $9.45M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $17.26M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $17.71M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $20.32M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $11.67M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $4.14M | Mar 19, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.40M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $352.48M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $168.87M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($44.37M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($17.25M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $143.91M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $141.19M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $145.65M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | ($42.12M) | Mar 3, 2020 |
| FY2019 | Dec 31, 2016 | ($8.87M) | Mar 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($336.73M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($174.39M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($89.42M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($45.87M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($325.57M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($254.43M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($179.50M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($102.73M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($45.21M) | Mar 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.09M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $22.79M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $132.33M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $15.37M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $131.65M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $58.15M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $65.07M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $58.35M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $51.40M | Mar 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (32) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (32) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.22M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 31.12M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 14.82M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 875,279 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 58.80M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 48.53M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 39.26M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 33.31M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 2.35M | Mar 19, 2019 |